Bioporto A-S News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.12.24	BioPorto commences process to appoint new Chair of the Board of Directors (GlobeNewswire)
14.11.24	BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 (GlobeNewswire)
13.11.24	Ausblick: Bioporto A-S stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
04.11.24	Grant of Warrants (GlobeNewswire)
30.10.24	Erste Schätzungen: Bioporto A-S stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
29.10.24	First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital (GlobeNewswire)
28.10.24	BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests (GlobeNewswire)
15.08.24	BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 (GlobeNewswire)
04.07.24	Grant of Warrants (GlobeNewswire)
24.06.24	Managers’ transactions (GlobeNewswire)
24.06.24	Changes of number of shares and votes in BioPorto A/S (GlobeNewswire)
18.06.24	Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S. (GlobeNewswire)
17.06.24	BioPorto A/S initiates a private placement of 50,000,000 new shares at market price. (GlobeNewswire)
30.05.24	BioPorto A/S Appoints Chief Financial Officer (GlobeNewswire)
08.05.24	First Quarter 2024: Strong growth in US sales of The NGAL Test (GlobeNewswire)
07.05.24	Ausblick: Bioporto A-S veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
30.04.24	Resolutions of Annual Geneal Meeting (GlobeNewswire)
23.04.24	Grant of warrants (GlobeNewswire)
10.04.24	BioPorto A/S Appoints Chief Legal Officer (GlobeNewswire)
05.04.24	New Board Candidate for the upcoming Annual Geneal Meeting (GlobeNewswire)
04.04.24	Notice convening the Annual General Meeting in BioPorto A/S (GlobeNewswire)
04.04.24	BioPorto Announces Annual Results for 2023 (GlobeNewswire)
02.04.24	BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer (GlobeNewswire)
22.02.24	BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 (GlobeNewswire)
20.02.24	Roche Diagnostics and BioPorto expand collaboration (GlobeNewswire)
09.01.24	BioPorto implements changes to the Executive Management. (GlobeNewswire)
09.12.23	Managers’ transactions (GlobeNewswire)
07.12.23	BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years (GlobeNewswire)
04.12.23	Resignation of Director (GlobeNewswire)
01.11.23	BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 (GlobeNewswire)
31.10.23	BioPorto provides interim Q3 results and revised 2023 Financial Guidance. (GlobeNewswire)
22.09.23	Grant of Warrants (GlobeNewswire)
19.09.23	BioPorto Initiates Search for new CFO as Neil Goldman Resigns (GlobeNewswire)
01.08.23	BioPorto Announces Interim Results for the First Six Months of 2023 (GlobeNewswire)
28.06.23	Managers’ transactions (GlobeNewswire)
23.06.23	BioPorto A/S announces completion of rights issue; total number of shares and voting rights (GlobeNewswire)
21.06.23	BioPorto A/S announces results of rights issue (GlobeNewswire)
30.05.23	BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed purs (GlobeNewswire)
23.05.23	Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act (GlobeNewswire)
10.05.23	BioPorto Announces Interim Results for the First Three Months of 2023 (GlobeNewswire)
27.04.23	Resolutions of the General Meeting of BioPorto A/S (GlobeNewswire)
25.04.23	Grant of Warrants (GlobeNewswire)
05.04.23	Notice convening the Annual General Meeting in BioPorto A/S (GlobeNewswire)
30.03.23	BioPorto Announces Annual Results for the Year ended December 31, 2022 (GlobeNewswire)
29.03.23	BioPorto Announces Financial Guidance for 2023 (GlobeNewswire)
29.03.23	US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. (GlobeNewswire)
16.02.23	Grant of warrants (GlobeNewswire)
10.05.22	Ausblick: Bioporto A-S zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
26.04.22	Erste Schätzungen: Bioporto A-S stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
09.03.22	Ausblick: Bioporto A-S informiert über die jüngsten Quartalsergebnisse (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bioporto A-S

Aktien Top/Flop

Meistgelesene Nachrichten